Bill Calls for Lyme Disease Treatment Protocol, More Education
A bill in the state Senate would endorse long-term antibiotic treatment for Lyme disease sufferers and call on the state to ramp up education on the disease.
The Pennsylvania Medical Society (PAMED) does not support Senate Bill 1199 because it would legislate what physicians must say to patients in the privacy of an exam room about treatment of a particular disease, interrupting the physician-patient relationship.
“Legislative attempts to practice medicine should be avoided. The medical community must have the flexibility to prescribe treatments as new medications and procedures are discovered and then proven,” Dan Kimball, MD, testified before the Senate Banking and Insurance Committee on June 22.
The PAMED House of Delegates in 2005 passed a resolution to oppose any legislation that attempts to define an acceptable standard of treatment for a specific disease.
While SB 1199 would require physicians to review with patients all Lyme disease treatments available in the Agency for Healthcare Research and Quality's National Guideline Clearinghouse, the treatments in this clearinghouse often conflict and their inclusion in the clearinghouse has not been evaluated by unbiased medical professionals.
In addition, because of longstanding policy, PAMED cannot offer its support to treatments, such as the long-term antibiotic treatment of Lyme disease, that have not been endorsed by the Centers for Disease Control and Prevention (CDC), the National Institutes of Health, or the Infectious Disease Society of America (IDSA). An independent panel has confirmed the IDSA’s stance on long-term antibiotic treatment.
PAMED does support a component of the bill that would increase education on the prevention, diagnosis, and treatment of Lyme disease with the assistance of health care provider professional associations, such as the Pennsylvania Medical Society.
Last Updated: 6/25/2010